709 filings
Page 8 of 36
D
7vljq
18 Jun 20
$10M in equity, sold $341.25K, 1 investor
5:07pm
CORRESP
16f45703c6b
18 Jun 20
Correspondence with SEC
12:00am
8-K
b4gc62ki2tag5s0lu
10 Jun 20
Entry into a Material Definitive Agreement
5:28pm
UPLOAD
ql1o9cvy
20 May 20
Letter from SEC
12:00am
8-K
g9fe18j
14 May 20
Viveve Reports First Quarter 2020 Financial Results and Provides Corporate Update
4:03pm
8-K
n5l9fh n1t9ehiy7fp
6 May 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:20pm
D
ir3hu45at
4 May 20
$3.23M in options / securities to be acquired, sold $3.23M, 9 investors
4:34pm
8-K
1b5 slt8o
24 Apr 20
Entry into a Material Definitive Agreement
5:00pm
8-K
m5u5kr4454g0kvy
17 Apr 20
Entry into a Material Definitive Agreement
8:10am
424B3
zvsax 1ziut0dunq
17 Apr 20
Prospectus supplement
7:51am
8-K
e62r9th 2fi
16 Apr 20
Viveve Announces Approval of Viveve 2.0 System in Canada
8:29am
8-K
4064sl7 zf11y5uyki8
15 Apr 20
Viveve Resubmits U.S. Investigational Device Exemption to FDA to Conduct New PURSUIT Trial for Improvement of Stress Urinary Incontinence
8:29am
8-K
h9wuqrg3
9 Apr 20
Viveve Announces Topline Results from Pivotal U.S. VIVEVE II Trial for Improvement of Sexual Function in Women
8:29am
8-K
62p1popf373d 9kwi
26 Mar 20
Viveve Announces Clearance of Next Generation 2.0 System in Taiwan
8:29am
S-8
o0im09ndxtgm3b
19 Mar 20
Registration of securities for employees
4:19pm